会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 27. 发明授权
    • Diagnosing genetic disorders
    • 诊断遗传疾病
    • US06949341B2
    • 2005-09-27
    • US10264126
    • 2002-10-03
    • Kenneth J. RothschildSanjay M. SonarJerzy Olejnik
    • Kenneth J. RothschildSanjay M. SonarJerzy Olejnik
    • A61K38/00A61K41/00C07C205/45C07C205/57C07D207/40C07D207/404C07D311/16C07D405/12C07D495/04C07H19/04C07H21/00C07K1/107C07K1/13C12P21/00G01N33/532C12Q1/68
    • C12Q1/6876A61K38/00A61K41/0042C07C205/45C07C205/57C07D207/404C07D311/16C07D405/12C07D495/04C07H19/04C07H21/00C07K1/1077C07K1/13C12P21/00C12Q1/6823G01N33/5306G01N33/532G01N33/58C12Q2523/319
    • This invention relates to agents and conjugates that can be used to detect and isolate target components from complex mixtures such as nucleic acids from biological samples, cells from bodily fluids, and nascent proteins from translation reactions. Agents comprise a detectable moiety bound to a photoreactive moiety. Conjugates comprise agents coupled to substrates by covalent bounds which can be selectively cleaved with the administration of electromagnetic radiation. Targets substances labeled with detectable molecules can be easily identified and separated from a heterologous mixture of substances. Exposure of the conjugate to radiation releases the target in a functional form and completely unaltered. Using photocleavable molecular precursors as the conjugates, label can be incorporated into macromolecules, the nascent macromolecules isolated and the label completely removed. The invention also relates to targets isolated with these conjugates which may be useful as pharmaceutical agents or compositions that can be administered to humans and other mammals. Useful compositions include biological agents such as nucleic acids, proteins, lipids and cytokines. Conjugates can also be used to monitor the pathway and half-life of pharmaceutical composition in vivo and for diagnostic, therapeutic and prophylactic purposes. The invention also relates to kits comprised of agents and conjugates that can be used for the detection of diseases, disorders and nearly any individual substance in a complex background of substances.
    • 本发明涉及可用于从复杂混合物检测和分离靶组分的试剂和缀合物,例如来自生物样品的核酸,来自体液的细胞和来自翻译反应的新生蛋白。 试剂包含与光反应性部分结合的可检测部分。 缀合物包括通过共价界限偶联到底物的试剂,其可以通过施用电磁辐射被选择性地切割。 目标可以用可检测分子标记的物质可以很容易地识别,并与物质的异源混合物分离。 缀合物暴露于放射线以功能形式释放靶,完全不变。 使用可光致发光的分子前体作为共轭物,标记可以并入大分子中,分离出新生大分子,并将标记完全除去。 本发明还涉及用这些缀合物分离的靶,其可用作可以施用于人和其它哺乳动物的药剂或组合物。 有用的组合物包括生物制剂如核酸,蛋白质,脂质和细胞因子。 缀合物也可用于监测药物组合物在体内和诊断,治疗和预防目的中的途径和半衰期。 本发明还涉及可用于检测疾病,病症和物质复杂背景中的几乎任何单一物质的试剂和缀合物的试剂盒。
    • 28. 发明授权
    • Dual markers
    • 双标记
    • US06596481B1
    • 2003-07-22
    • US09335018
    • 1999-06-17
    • Kenneth J. RothschildJerzy OlejnikSanjay M. Sonar
    • Kenneth J. RothschildJerzy OlejnikSanjay M. Sonar
    • C12Q168
    • C12Q1/6876A61K38/00A61K41/0042C07C205/45C07C205/57C07D207/404C07D311/16C07D405/12C07D495/04C07H19/04C07H21/00C07K1/1077C07K1/13C12P21/00G01N33/532Y02A50/473
    • The invention is directed to methods for the non-radioactive labeling, detection, quantitation and isolation of nascent proteins translated in a cellular or cell-free translation system. tRNA molecules are misaminoacylated with non-radioactive markers which may be non-native amino acids, amino acid analogs or derivatives, or substances recognized by the protein synthesizing machinery. Markers may comprise cleavable moieties, detectable labels, reporter properties wherein markers incorporated into protein can be distinguished from unincorporated markers, or coupling agents which facilitate the detection and isolation of nascent protein from other components of the translation system. The invention also comprises proteins prepared using misarminoacylated tRNAs which can be utilized in pharmaceutical compositions for the treatment of diseases and disorders in humans and other mammals, and kits which may be used for the detection of diseases and disorders.
    • 本发明涉及用于在细胞或无细胞翻译系统中翻译的新生蛋白的非放射性标记,检测,定量和分离的方法。 tRNA分子被非放射性标记物错氨基酰化,其可以是非天然氨基酸,氨基酸类似物或衍生物,或由蛋白质合成机理识别的物质。 标记可以包含可切割部分,可检测标记,报告基因特性,其中掺入蛋白质的标记可以与非组合标记物或促进从翻译系统的其他组分检测和分离新生蛋白质的偶联剂区别。 本发明还包括使用可能用于治疗人类和其他哺乳动物疾病和病症的药物组合物中的未甲酰基化的tRNA制备的蛋白质,以及可用于检测疾病和病症的试剂盒。
    • 29. 发明授权
    • Detection of markers in nascent proteins
    • 新生蛋白中标记物的检测
    • US06358689B1
    • 2002-03-19
    • US09583243
    • 2000-05-31
    • Kenneth J. RothschildJerzy Olejnik
    • Kenneth J. RothschildJerzy Olejnik
    • C12Q168
    • C07D207/404A61K38/00A61K41/0042C07C205/45C07C205/57C07D311/16C07D405/12C07D495/04C07H19/04C07H21/00C07K1/1077C07K1/13C12P21/00C12Q1/68G01N33/532G01N33/582
    • The invention is directed to methods for the non-radioactive labeling, detection, quantitation and isolation of nascent proteins translated in a cellular or cell-free translation system. tRNA molecules are misaminoacylated with non-radioactive markers which may be non-native amino acids, amino acid analogs or derivatives, or substances recognized by the protein synthesizing machinery. Markers may comprise cleavable moieties, detectable labels, reporter properties wherein markers incorporated into protein can be distinguished from unincorporated markers, or coupling agents which facilitate the detection and isolation of nascent protein from other components of the translation system. The invention also comprises proteins prepared using misaminoacylated tRNAs which can be utilized in pharmaceutical compositions for the treatment of diseases and disorders in humans and other mammals, and kits which may be used for the detection of diseases and disorders.
    • 本发明涉及用于在细胞或无细胞翻译系统中翻译的新生蛋白的非放射性标记,检测,定量和分离的方法。 tRNA分子被非放射性标记物错氨基酰化,其可以是非天然氨基酸,氨基酸类似物或衍生物,或由蛋白质合成机理认可的物质。 标记可以包含可切割部分,可检测标记,报告基因特性,其中掺入蛋白质的标记可以与非组合标记物或促进从翻译系统的其他组分检测和分离新生蛋白质的偶联剂区分开来。 本发明还包括使用可用于治疗人类和其他哺乳动物疾病和病症的药物组合物中的使用错氨基酰化tRNA制备的蛋白质,以及可用于检测疾病和病症的试剂盒。
    • 30. 发明授权
    • Electrophoresis of nascent proteins
    • 新生蛋白的电泳
    • US06344320B1
    • 2002-02-05
    • US09307579
    • 1999-05-07
    • Kenneth J. RothschildSanjay M. SonarJerzy Olejnik
    • Kenneth J. RothschildSanjay M. SonarJerzy Olejnik
    • C12Q168
    • A61K41/0042A61K38/00C07C205/45C07C205/57C07D207/404C07D311/16C07D405/12C07D495/04C07H19/04C07H21/00C07K1/1077C07K1/13C12P21/00C12Q1/6883G01N33/58
    • The invention is directed to methods for the non-radioactive labeling, detection, quantitation and isolation of nascent proteins translated in a cellular or cell-free translation system. tRNA molecules are misaminoacylated with non-radioactive markers which may be non-native amino acids, amino acid analogs or derivatives, or substances recognized by the protein synthesizing machinery. Markers may comprise cleavable moieties, detectable labels, reporter properties wherein markers incorporated into protein can be distinguished from unincorporated markers, or coupling agents which facilitate the detection and isolation of nascent protein from other components of the translation system. The invention also comprises proteins prepared using misaminoacylated tRNAs which can be utilized in pharmaceutical compositions for the treatment of diseases and disorders in humans and other maninials, and kits which may be used for the detection of diseases and disorders.
    • 本发明涉及用于在细胞或无细胞翻译系统中翻译的新生蛋白的非放射性标记,检测,定量和分离的方法。 tRNA分子被非放射性标记物错氨基酰化,其可以是非天然氨基酸,氨基酸类似物或衍生物,或由蛋白质合成机理识别的物质。 标记可以包含可切割部分,可检测标记,报告基因特性,其中掺入蛋白质的标记可以与非组合标记物或促进从翻译系统的其他组分检测和分离新生蛋白质的偶联剂区别。 本发明还包括使用可以用于治疗人类和其他肌肉疾病和病症的药物组合物中的使用错氨基酰化tRNA制备的蛋白质,以及可用于检测疾病和病症的试剂盒。